Paper Details

  1. Home
  2. Paper Details

Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716.

Author:

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Decitabine is a drug used to treat certain types of leukemia. It works by causing changes in DNA that can lead to cell death in leukemia cells. The drug has shown limited efficacy against solid tumors but is more effective in treating hematologic malignancies. Decitabine is currently being studied in various clinical trials for different types of leukemia and in combination with other treatments.
Paper Details　
Original Abstract of the Article :
Decitabine [NSC 127716, DAC, dezocitidine, Aza dC, 2'-deoxy-5-azacytidine, Dacogen( trade mark )] is a deoxycytidine and cytarabine derivative with potent antileukaemic activity, originated by Pharmachemie. This antimetabolite is able to induce in vitro gene activation and cellular differentiation b...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2165/00126839-200304060-00004

データ提供：米国国立医学図書館（NLM）

Decitabine: A Promising Treatment for Hematological Malignancies

This article explores the development and clinical potential of decitabine, a deoxycytidine and cytarabine derivative with potent antileukaemic activity. The researchers discuss the drug's mechanism of action, clinical trial results, and ongoing research efforts to assess its efficacy in treating various types of leukemia and other hematological malignancies.

Decitabine and DNA Hypomethylation

Decitabine's unique mechanism of action involves inducing gene activation and cellular differentiation through DNA hypomethylation. This property makes it a promising candidate for treating hematological malignancies, particularly leukemia.

Potential Treatment for Hematological Cancers

The article highlights the promising results of clinical trials investigating decitabine's efficacy in treating various hematological malignancies, including myelodysplastic syndrome (MDS) and chronic myeloid leukemia (CML). The research suggests that decitabine holds potential as a valuable therapeutic option for these diseases.

Dr.Camel's Conclusion

This article provides a detailed overview of decitabine's development and clinical potential. Decitabine's unique mechanism of action and promising results in clinical trials suggest its potential as an effective treatment for various hematological malignancies. The ongoing research efforts to further understand its efficacy and safety profile are crucial for optimizing its use and improving patient outcomes.

Date :
  1. Date Completed 2004-04-12
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

14584964

DOI: Digital Object Identifier

10.2165/00126839-200304060-00004

Related Literature

Article Analysis
・Effects of decitabine injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.